种族肿瘤学为其药物RC220启动了两项新的临床方案,针对的是难于治疗的白血病和肺癌。 Race Oncology launched two new clinical programs for its drug RC220 targeting hard-to-treat leukemias and lung cancers.

种族肿瘤学为其RC220药物启动了两个新的临床方案,其对象是急性间流质白血病和经EGFR改型的非小型细胞肺癌,其依据是对药物机制的新认识,这种新认识可以加快监管路径。 Race Oncology has launched two new clinical programs for its drug RC220, targeting acute myeloid leukemia and EGFR-mutated non-small cell lung cancer, based on new insights into the drug’s mechanism that may enable a faster regulatory path. 此举将该公司的后期输油管道扩大到治疗抗药性常见的高需求癌症地区。 The move expands the company’s late-stage pipeline into high-need cancer areas where treatment resistance is common. 2025年11月16日的公告反映了种族肿瘤学迅速推进有前途的肿瘤学候选人的战略。 The announcement, made November 16, 2025, reflects Race Oncology’s strategy to rapidly advance promising oncology candidates.